Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Nelonemdaz in Patients With Acute Ischemic Stroke

NCT05041010 is registered in ClinicalTrials.gov with GNT Pharma as lead sponsor.

NCT NCT05041010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05041010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Nelonemdaz in Patients With Acute Ischemic Stroke
Lead sponsor
GNT Pharma
Phase
Phase 3
Overall status
Unknown status
Start date
December 25, 2021
Completion date
January 31, 2025
Enrollment
496 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke